CRIS Current Research Information System

PALLONI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.404
AS - Asia 4.387
EU - Europa 2.677
AF - Africa 322
SA - Sud America 175
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.325
VN - Vietnam 1.179
SG - Singapore 1.133
CN - Cina 1.128
IT - Italia 806
GB - Regno Unito 350
SE - Svezia 336
DE - Germania 286
HK - Hong Kong 228
KR - Corea 182
IN - India 172
FR - Francia 148
NL - Olanda 142
IE - Irlanda 123
CH - Svizzera 117
BR - Brasile 114
FI - Finlandia 111
CI - Costa d'Avorio 106
BD - Bangladesh 85
RU - Federazione Russa 83
SC - Seychelles 65
JP - Giappone 52
NG - Nigeria 50
CA - Canada 44
ZA - Sudafrica 43
TG - Togo 40
PH - Filippine 32
ID - Indonesia 29
JO - Giordania 27
AT - Austria 26
BG - Bulgaria 21
TR - Turchia 21
GR - Grecia 20
IQ - Iraq 20
MX - Messico 19
AR - Argentina 18
EE - Estonia 18
UA - Ucraina 17
TW - Taiwan 16
BE - Belgio 15
PK - Pakistan 15
PL - Polonia 15
TH - Thailandia 14
CL - Cile 12
PS - Palestinian Territory 11
SA - Arabia Saudita 10
ES - Italia 9
LT - Lituania 9
EC - Ecuador 8
PY - Paraguay 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
MA - Marocco 5
MY - Malesia 5
NI - Nicaragua 5
PT - Portogallo 5
UZ - Uzbekistan 5
CO - Colombia 4
CR - Costa Rica 4
DZ - Algeria 4
PE - Perù 4
RO - Romania 4
AU - Australia 3
BO - Bolivia 3
DK - Danimarca 3
IR - Iran 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
CZ - Repubblica Ceca 2
EG - Egitto 2
HN - Honduras 2
HU - Ungheria 2
KZ - Kazakistan 2
LB - Libano 2
NP - Nepal 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
GE - Georgia 1
GN - Guinea 1
HT - Haiti 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
MT - Malta 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
Totale 11.970
Salva come PNG Salva come JPEG
Città #
Singapore 817
Dallas 689
Ashburn 470
Hefei 398
Chandler 318
Ho Chi Minh City 273
San Jose 272
Southend 267
Hanoi 254
Fairfield 224
Hong Kong 214
Seoul 160
Boardman 156
Bologna 156
Santa Clara 135
Houston 130
Dong Ket 126
Beijing 125
Dublin 123
Bern 107
Abidjan 106
Princeton 100
New York 99
Wilmington 92
Helsinki 89
Seattle 89
Woodbridge 86
Council Bluffs 78
Rome 71
Los Angeles 67
Lauterbourg 65
Cambridge 64
Frankfurt am Main 59
Ann Arbor 58
Milan 51
Tokyo 43
Lomé 40
Da Nang 38
Buffalo 36
Bengaluru 35
Turin 35
Berlin 32
Redmond 32
Haiphong 30
Nanjing 29
Redondo Beach 28
Amman 26
London 25
Westminster 25
Abeokuta 24
Tongling 24
São Paulo 23
Munich 22
Sofia 21
Shanghai 20
Florence 19
Jakarta 18
Lappeenranta 18
Toronto 17
Jinan 16
Johannesburg 16
San Diego 16
Biên Hòa 15
Hải Dương 15
Amsterdam 14
Guangzhou 14
Padova 14
Medford 13
Nuremberg 13
Orem 13
Ravenna 13
Brussels 12
Can Tho 12
Hyderabad 12
Bến Tre 11
Chicago 11
Phoenix 11
Shenyang 11
Thái Nguyên 11
Vienna 11
Brooklyn 10
Denver 10
Des Moines 10
Groningen 10
Istanbul 10
Montreal 10
Olalla 10
Warsaw 10
Atlanta 9
Baghdad 9
Chennai 9
Falkenstein 9
Halhul 9
Stockholm 9
Tianjin 9
Wuhan 9
Wuxi 9
Bari 8
Bắc Ninh 8
Mexico City 8
Totale 7.707
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 461
Adjuvant treatment in biliary tract cancer 345
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 311
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 304
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 303
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 284
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 252
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 243
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 234
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 229
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 228
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 219
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 219
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 219
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 215
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 211
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 209
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 208
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 208
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 207
Bone metastases in biliary cancers: A multicenter retrospective survey 202
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 202
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 200
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 197
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 197
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 195
In Reply 195
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 191
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 190
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 189
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 187
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review 181
State of the art biological therapies in pancreatic cancer 180
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 180
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 180
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 179
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 178
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 177
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 169
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree. 166
Chemotherapy in Patients with Advanced Cholangiocarcinoma 164
Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster 162
Hacking pancreatic cancer: Present and future of personalized medicine 162
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 160
Classic versus innovative strategies for immuno-therapy in pancreatic cancer 153
Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study 152
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? 149
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 142
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue 139
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 129
Experimental HER2- targeted therapies for biliary tract cancer 128
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 128
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 125
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma 121
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 120
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 119
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 111
Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma? 106
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 106
Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma 104
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 103
Nivolumab: an investigational agent for the treatment of biliary tract cancer 102
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 87
The use of comprehensive complication Index® in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center 83
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 80
Concurrent Chemoradiation Outperforms Chemotherapy Alone in the Treatment of Unresectable Biliary Tract Cancers: A Meta-analysis. 79
Does Adjuvant Therapy in Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas Improve Survival? A Systematic Review and Meta‐Analysis Using Trial Sequential Analysis 58
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 50
Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma 39
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma 31
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study 29
Totale 12.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021212 0 0 0 0 0 0 0 0 0 0 0 212
2021/20221.067 68 37 43 75 70 34 26 73 135 113 236 157
2022/20231.407 125 203 71 141 101 101 45 83 224 64 92 157
2023/2024471 76 55 32 42 37 81 20 27 15 37 28 21
2024/20251.888 100 200 163 119 169 73 114 123 61 186 173 407
2025/20265.872 530 626 992 422 475 238 517 197 991 397 239 248
Totale 12.265